JP2007504237A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504237A5
JP2007504237A5 JP2006525420A JP2006525420A JP2007504237A5 JP 2007504237 A5 JP2007504237 A5 JP 2007504237A5 JP 2006525420 A JP2006525420 A JP 2006525420A JP 2006525420 A JP2006525420 A JP 2006525420A JP 2007504237 A5 JP2007504237 A5 JP 2007504237A5
Authority
JP
Japan
Prior art keywords
antigen
complex
scaffold
cell
scaffold complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006525420A
Other languages
English (en)
Japanese (ja)
Other versions
JP5097400B2 (ja
JP2007504237A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/028492 external-priority patent/WO2005037190A2/en
Publication of JP2007504237A publication Critical patent/JP2007504237A/ja
Publication of JP2007504237A5 publication Critical patent/JP2007504237A5/ja
Application granted granted Critical
Publication of JP5097400B2 publication Critical patent/JP5097400B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006525420A 2003-09-03 2004-09-01 複合ワクチン Expired - Fee Related JP5097400B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50021603P 2003-09-03 2003-09-03
US60/500,216 2003-09-03
PCT/US2004/028492 WO2005037190A2 (en) 2003-09-03 2004-09-01 Multiplex vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011109512A Division JP2011231111A (ja) 2003-09-03 2011-05-16 複合ワクチン

Publications (3)

Publication Number Publication Date
JP2007504237A JP2007504237A (ja) 2007-03-01
JP2007504237A5 true JP2007504237A5 (https=) 2007-09-27
JP5097400B2 JP5097400B2 (ja) 2012-12-12

Family

ID=34465066

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006525420A Expired - Fee Related JP5097400B2 (ja) 2003-09-03 2004-09-01 複合ワクチン
JP2011109512A Withdrawn JP2011231111A (ja) 2003-09-03 2011-05-16 複合ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011109512A Withdrawn JP2011231111A (ja) 2003-09-03 2011-05-16 複合ワクチン

Country Status (7)

Country Link
US (1) US20070014807A1 (https=)
EP (2) EP2481422A3 (https=)
JP (2) JP5097400B2 (https=)
AU (1) AU2004281634B2 (https=)
CA (1) CA2537900A1 (https=)
IL (1) IL174020A0 (https=)
WO (1) WO2005037190A2 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
AU2002322009A1 (en) 2001-05-18 2002-12-03 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US9492400B2 (en) * 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
CN101203239B (zh) * 2005-03-31 2014-09-17 莱顿大学医药中心 诊断、预防和治疗分枝杆菌感染和结核疾病的方法和装置
PT2347775T (pt) * 2005-12-13 2020-07-14 The President And Fellows Of Harvard College Estruturas em andaime para transplante celular
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
ES2776100T3 (es) * 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
WO2008147456A2 (en) * 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2008124632A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
KR20100034010A (ko) * 2007-06-15 2010-03-31 임뮤룩스, 인코포레이티드 Ｔｎｆ­ｒ 효능제 치료 요법의 독성을 경감시키기 위한 ｔｌｒ 효능제 및／또는 타입 1 인터페론의 용도
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
EP2630966B1 (en) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
CA2721366C (en) 2008-04-17 2017-06-06 Elizabeth Ann Vasievich Stimulation of an immune response by enantiomers of cationic lipids
US9012399B2 (en) 2008-05-30 2015-04-21 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
KR20120022984A (ko) * 2009-04-21 2012-03-12 셀렉타 바이오사이언시즈, 인크. Ｔｈ１ 편향 반응을 제공하는 면역나노치료법
CA2762653A1 (en) * 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
EP2461828B1 (en) 2009-07-31 2017-06-21 President and Fellows of Harvard College Programming of cells for tolerogenic therapies
JP2013504599A (ja) * 2009-09-14 2013-02-07 ベイラー リサーチ インスティテュート ランゲルハンス細胞に向けられたワクチン
WO2011109834A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
AU2011258165B2 (en) * 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2011152995A1 (en) * 2010-06-04 2011-12-08 Bolt Biopharma, Inc. Synthetic proteins containing t cell epitopes for use as immunogenic compositions
EP2585053A4 (en) 2010-06-25 2014-02-26 Harvard College COMMON RELEASE OF STIMULATING AND HEMMING FACTORS FOR THE PRODUCTION OF TEMPORARY STABILIZED AND SPATULARLY LIMITED ZONES
JP6104806B2 (ja) 2010-10-06 2017-03-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
AU2011312107B2 (en) 2010-10-08 2016-06-23 R.P. Scherer Technologies, Llc Oral vaccine fast-dissolving dosage form using starch
JP2013540162A (ja) * 2010-10-22 2013-10-31 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 抗原特異的な寛容を誘導する微粒子およびその使用
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
US9603894B2 (en) 2010-11-08 2017-03-28 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
WO2012148684A1 (en) 2011-04-27 2012-11-01 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP2701745B1 (en) 2011-04-28 2018-07-11 President and Fellows of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
CN103648489A (zh) * 2011-05-11 2014-03-19 儿童医疗中心有限公司 多抗原提呈免疫原性组合物及其方法和用途
WO2012167230A1 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
US20130034482A1 (en) * 2011-08-05 2013-02-07 Chevron U.S.A Inc. Reduction of oxides of nitrogen in a gas stream using molecular sieve ssz-23
CN104066444A (zh) * 2011-09-12 2014-09-24 Pds生物科技公司 微粒疫苗制剂
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
CN104244929B (zh) 2012-04-16 2017-04-05 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
JP6494527B2 (ja) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
US10441649B2 (en) * 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EP3411475B1 (en) 2016-02-06 2025-08-27 President and Fellows of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
JP6121597B1 (ja) * 2016-06-09 2017-04-26 株式会社スリービー 免疫応答活性化サイトカイン産生促進剤およびＴｈ１７細胞分化促進剤
CN115404196A (zh) 2016-07-13 2022-11-29 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
CN110418651A (zh) 2016-08-02 2019-11-05 哈佛学院院长等 用于调节免疫应答的生物材料
AU2018243910B2 (en) 2017-03-28 2025-04-10 The Children's Medical Center Corporation A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
WO2018237221A1 (en) 2017-06-23 2018-12-27 Nosocomial Vaccine Corporation IMMUNOGENIC COMPOSITIONS
CA3084957A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
IL281204B2 (en) 2018-09-12 2025-07-01 Affinivax Inc Multivalent pneumococcal vaccines
JP7535791B2 (ja) 2018-09-12 2024-08-19 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌融合タンパク質ワクチン
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
IL326005A (en) 2021-09-09 2026-03-01 Affinivax Inc Multivalent pneumococcal vaccines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303160T1 (de) * 1993-08-11 2005-09-15 Jenner Technologies Impfstoff gegen prostatakrebs
GB2282813A (en) * 1993-10-15 1995-04-19 Merck & Co Inc Annular antigen scaffolds comprising thioether linkages
DE69834808T2 (de) * 1997-03-27 2007-06-06 Institut Pasteur Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung
PT1053325E (pt) * 1998-02-05 2006-05-31 Glaxosmithkline Biolog Sa Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
NZ506071A (en) * 1998-02-19 2003-05-30 Harvard College Monovalent, multivalent, and multimeric major histocompatibility complex (MHC) binding domain fusion proteins and conjugates, and uses therefore
EP1064022A4 (en) * 1998-03-13 2004-09-29 Epimmune Inc HLA BINDING PROTEINS AND THEIR USE
IL141868A0 (en) * 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination
GB0018901D0 (en) * 2000-08-03 2000-09-20 Biovation Ltd Peptides presented by cells
EP1911461B1 (en) * 2000-10-19 2011-12-07 Epimmune Inc. HLA class I and II binding peptides and their uses
WO2002066056A2 (en) * 2001-02-19 2002-08-29 Pharmexa A/S Synthetic vaccines comprising polyhydroxypolymer carriers
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
EP1409650B1 (en) * 2001-05-30 2006-04-12 Fondazione Telethon Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof
JP3642301B2 (ja) * 2001-07-31 2005-04-27 日本電気株式会社 パケット監視方式
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
US8637305B2 (en) * 2001-11-07 2014-01-28 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design

Similar Documents

Publication Publication Date Title
JP2007504237A5 (https=)
Storni et al. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles
CN103402539B (zh) 一种用于产生对抗病原体的持久免疫和保护的合成免疫原
Fifis et al. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice
JP2007501602A5 (https=)
TW514530B (en) Tumor vaccines and methods for their production
JP2011519847A5 (https=)
US20230172869A1 (en) A nano-enabled vaccination approach for coronavirus disease (covid-19) and other viral diseases
WO2012122396A1 (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
JP2020506690A5 (https=)
KR20080013850A (ko) 면역원성 분자
JP4713638B2 (ja) ナチュラルキラーｔ細胞のリガンドと抗原を積載したｂ細胞を媒介とするワクチン
RU2009110969A (ru) Композиции, вызывающие специфический ответ цитотоксических т-лимфоцитов, включающие лимфоаблативное соединение и молекулу, содержащую антигенные последовательности и нацеленную на специализированные антигенпрезентирующие клетки
JP2010508857A5 (https=)
Peacey et al. Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response
JP2021519762A (ja) ワクチン組成物
JPWO2021163438A5 (https=)
TWI754817B (zh) 以人工混雜ｔ輔助細胞抗原決定位以有限度的ｔ細胞發炎反應促進目標抗體的生產
EP2519263B1 (en) Lipopeptide- and lipoprotein-conjugates and its use
CN107286244B (zh) 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
CN113906046A (zh) 具有包含经修饰半胱氨酸的氧化还原酶基序的免疫原性肽
EP1029549B1 (en) Formulation of nucleic acids and acemannan
KR20180080178A (ko) 세균성 백신 및 바이러스성 백신 방법
EP3517542B1 (en) Dendritic-cell-targeted peptide, fusion peptide utilizing said peptide, and vaccine utilizing said fusion peptide
CA2560891A1 (fr) Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations